Table 2. Hazards of myocardial infarction, stroke, and type 2 diabetes incidence according to the treatment group.
| Treatment groups | Event | Follow-up duration (person-years) | Incidence rate (per 1,000 person-years) | HR (95% CI) | p-value | |
|---|---|---|---|---|---|---|
| Myocardial infarction | ||||||
| Statin monotherapy group (n=5,775) | 66 | 43,242.69 | 1.52627 | 1.000 (ref.) | 0.5984 | |
| Statin-ezetimibe combination therapy group (n=1,155) | 14 | 8,248.83 | 1.69721 | 1.168 (0.656–2.081) | ||
| Stroke | ||||||
| Statin monotherapy group (n=5,775) | 86 | 43,165.13 | 1.99235 | 1.000 (ref.) | 0.8024 | |
| Statin-ezetimibe combination therapy group (n=1,155) | 17 | 8,236.02 | 2.06410 | 1.069 (0.635–1.799) | ||
| Type 2 diabetes | ||||||
| Statin monotherapy group (n=5,775) | 800 | 40,768.66 | 19.6229 | 1.000 (ref.) | 0.3170 | |
| Statin-ezetimibe combination therapy group (n=1,155) | 162 | 7708.62 | 21.0154 | 1.090 (0.921–1.291) | ||
HR, hazard ratio; CI, confidence interval.